Rgenix Secures $33,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    310 East 67th Street New York, NY 10065 USA
  • Company Description
    Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.
  • M&A Terms
  • Venture Investor
    Novo Ventures
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Partnership for New York City Fund
  • Venture Investor
    Alexandria Venture Investments

Trending on Xconomy